Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class III · Low risk

Fabior (tazarotene)

Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

Terminated Wrong potency / content Mayne Pharma Inc NDC 51862-295-10 D-0616-2018
Class III · Low risk

Flucanazole Injection

Superpotent and Failed Stability Specifications; out of specification results for assay and water vapor permeability

Terminated Wrong potency / content Renaissance Lakewood, LLC NDC 36000-006-10 D-0605-2018
Class II · Moderate risk

PVP Scrub Solution

Subpotent Drug: product not meeting the iodine assay level requirements through the labeled expiry.

Terminated Wrong potency / content Medline Industries Inc NDC 53329-938-04 D-0546-2018
Class III · Low risk

Cefuroxime

Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date.

Terminated Wrong potency / content JCB Laboratories LLC D-0246-2018
Class II · Moderate risk

Viokace (pancrelipase)

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Terminated Wrong potency / content Allergan NDC 58914-117-10 D-0154-2018